Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently shared thoughts on. Cramer said that the company needs to “broaden the portfolio,” as he remarked:
“Look, I think Amgen needs to do something because they’ve gotta broaden the portfolio where they need to be able to tell a little bit better story about some of the things that, they have a lot of good medicines, and they had a really good quarter last night.”
Photo by christina victoria on Unsplash
Amgen Inc. (NASDAQ:AMGN) manufactures human therapeutics for cancer, cardiovascular, inflammatory, and bone disorders. Its main products include Enbrel, Prolia, Repatha, Otezla, and Kyprolis. Cramer mentioned the company during the June 25 episode and said:
“Unlike Mounjaro or Ozempic, which needed to be injected once a week, Amgen’s MariTide is one shot per month. I prefer monthly over weekly when it comes to injections any day… So what did we learn when Amgen presented on Monday afternoon? First, the market didn’t like it. The stock sold off. Hard response… There… [was] some genuinely new information too. I’m talking about the Phase 1 trial, data from the separate trial, studying much lower starting doses of MariTide with different escalation schedules, far less vomiting at the low doses…
